Ipsen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IPSEN, and what generic alternatives to IPSEN drugs are available?
IPSEN has four approved drugs.
There are thirty-four US patents protecting IPSEN drugs.
There are two hundred and seventy-five patent family members on IPSEN drugs in forty-six countries and twenty-six supplementary protection certificates in fifteen countries.
Summary for Ipsen
| International Patents: | 275 |
| US Patents: | 34 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Ipsen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | 11,583,539 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | 11,801,226 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-004 | Aug 16, 2023 | RX | Yes | No | 9,314,439 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-004 | Aug 16, 2023 | RX | Yes | No | 11,622,959 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | RX | Yes | Yes | 10,011,633 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ipsen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-002 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
| Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-003 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
| Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-001 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ipsen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 11201810658P | ⤷ Try a Trial |
| Mexico | 2020013839 | ⤷ Try a Trial |
| Taiwan | I778942 | ⤷ Try a Trial |
| European Patent Office | 2861210 | ⤷ Try a Trial |
| Hong Kong | 1223566 | ⤷ Try a Trial |
| Colombia | 2020015772 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ipsen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1746976 | 122017000042 | Germany | ⤷ Try a Trial | PRODUCT NAME: LRINOTECAN SUCROSOFAT-SALZ, WIE Z.B. LRINOTECAN SUCROSOFAT-SALZ IN EINEM PEGYLIERTEN LIPOSOM WIE BEISPIELWEISE EINEM LIPOSOM, DAS 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLIN, CHOLESTERIN UND N-(OMEGA-METHOXYPOLY(ETHYLENGLYKOL) (MOLEKULARGEWICHT 2000)OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMIN Z.B. IM MOLVERHAELTNIS 3:2:0,015 UMFASST.; REGISTRATION NO/DATE: EU/1/16/1130 20161014 |
| 3400944 | CA 2022 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719 |
| 3400944 | C202130067 | Spain | ⤷ Try a Trial | PRODUCT NAME: ODEVIXIBAT; NATIONAL AUTHORISATION NUMBER: EU/1/21/1566; DATE OF AUTHORISATION: 20210716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1566; DATE OF FIRST AUTHORISATION IN EEA: 20210716 |
| 0137145 | SPC/GB97/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
| 1746976 | CA 2017 00030 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 |
| 3400944 | SPC/GB21/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ODEVIXIBAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING ODEVIXIBAT SESQUIHYDRATE; REGISTERED: UK EU/1/21/1566(NI) 20210719; UK PLGB 36216/0001 20210719; UK PLGB 36216/0002 20210719 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
